Join the Cariprazine group to help and get support from people like you.
Cariprazine News
U.S. FDA Approves Vraylar (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder
Approval marks fourth indication for Vraylar, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant...
FDA Approves Expanded Use of Vraylar (cariprazine) in the Treatment of Bipolar Depression
DUBLIN and BUDAPEST, Hungary, May 28, 2019 /PRNewswire/ – Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has approved a...
Allergan Receives FDA Approval for Vraylar (cariprazine) in the Maintenance Treatment of Schizophrenia
DUBLIN, Nov. 13, 2017 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Vraylar...
FDA Approves Vraylar (cariprazine) for Schizophrenia and Bipolar Disorder
September 17, 2015 – The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults. “Schizophrenia and bipolar disorder c...
Further information
Related condition support groups
Major Depressive Disorder, Bipolar Disorder, Schizophrenia